Persantin Preceding Elective PCI

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study the investigators will investigate whether a short pretreatment (3-7 days) with dipyridamole 200mg twice daily will protect patients against myocardial injury sustained during an elective dotter operation of the coronary arteries (PCI).

The investigators hypothesize that dipyridamole can reduce myocardial injury sustained during elective PCI.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Treatments: Dipyridamole

Criteria

Inclusion Criteria:

• Patients accepted for elective single, native vessel (left anterior descending, right coronary artery or ramus circumflexus (LAD, RCA or RCX)) PCI in the RUNMC

• Troponin-I < 0,20 mmol/L at screening

• Signed Informed consent

Exclusion Criteria:

• unstable angina

• recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion

• 3-Vessel disease as seen on coronary angiogram

• Stenotic lesion in main stem as seen on coronary angiogram

• CABG in medical history

• asthma (recurrent episodes of dyspnoea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)

• Treatment with insulin

• Use of prescribed oral anticoagulants (coumarin derivates)

• Use of oral corticosteroids

• Use of sulfonylurea derivates (glibenclamide, tolbutamide, gliclazide, glimepiride)

• Use of heparin or low molecular weight heparin

• Use of metformin

• Use of dipyridamole

• Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAID's)